Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss

Jennifer Hoffmann, Alex Alt, Jihong Lin, Günther Lochnit, Uwe Schubert, Erwin Schleicher, Triantaphyllos Chavakis, Michael Brownlee, Fokko J. Van der Woude, Klaus T. Preissner, Hans Peter Hammes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hyperglycemia-induced mitochondrial overproduction of reactive oxygen species leads to the activation of different biochemical pathways involved in endothelial damage of the diabetic retina. Tenilsetam [(±)-3-(2-thienyl)-2-piperazinone] is a dicarbonyl scavenger in the millimolar range and a transition metal ion chelator in the micromolar range. We tested its effect on experimental diabetic retinopathy, and on endothelial cell characteristics in vitro. Streptozotocin diabetic male Wistar rats (60mg/kg BW) received 50 mg/kg BW tenilsetam (D-T) for 36 weeks, or no treatment (D). The impact of tenilsetam (0-30 mM) on endothelial proliferation, apoptosis, sprouting, cytokine-induced leucocyte-endothelial interaction, and VEGF expression was tested in vitro. Tenilsetam did not affect glycemic control or body weight in diabetic animals. The 3.7 fold increase in acellular capillaries in diabetic rats [p<0.001 vs. non-diabetic controls (N)] was reduced by 70% (p<0.001) through treatment, but pericyte loss (D vs. N -33%; p<0.001) remained unaffected. In vitro, tenilsetam inhibited endothelial proliferation at lower doses, while inducing apoptosis at high doses. Leucocyte adhesion was only inhibited at high doses. Sprouting angiogenesis of bovine retinal endothelial cells was promoted at lower doses (≤ 10 mM). At micromolar concentrations, endothelial VEGF expression was upregulated by 100%. Long-term treatment with the AGE-inhibitor and iron-chelating compound tenilsetam inhibits the formation of acellular capillaries without correcting pericyte loss. The compound has dose-dependent effects on endothelial cell function. These data suggest that, independent of known properties, tenilsetam shows important rescue functions on endothelial cells which could be useful for the treatment of early diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)689-695
Number of pages7
JournalThrombosis and Haemostasis
Volume95
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Pericytes
Diabetic Retinopathy
Endothelial Cells
Vascular Endothelial Growth Factor A
Leukocytes
Iron Compounds
Apoptosis
tenilsetam
Streptozocin
Chelating Agents
Hyperglycemia
Retina
Wistar Rats
Reactive Oxygen Species
Metals
Body Weight
Ions
Cytokines

Keywords

  • Endothelial survival
  • Experimental diabetic retinopathy
  • Pericytes
  • Tenilsetam
  • VEGF

ASJC Scopus subject areas

  • Hematology

Cite this

Hoffmann, J., Alt, A., Lin, J., Lochnit, G., Schubert, U., Schleicher, E., ... Hammes, H. P. (2006). Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss. Thrombosis and Haemostasis, 95(4), 689-695. https://doi.org/10.1160/TH05-11-0725

Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss. / Hoffmann, Jennifer; Alt, Alex; Lin, Jihong; Lochnit, Günther; Schubert, Uwe; Schleicher, Erwin; Chavakis, Triantaphyllos; Brownlee, Michael; Van der Woude, Fokko J.; Preissner, Klaus T.; Hammes, Hans Peter.

In: Thrombosis and Haemostasis, Vol. 95, No. 4, 04.2006, p. 689-695.

Research output: Contribution to journalArticle

Hoffmann, J, Alt, A, Lin, J, Lochnit, G, Schubert, U, Schleicher, E, Chavakis, T, Brownlee, M, Van der Woude, FJ, Preissner, KT & Hammes, HP 2006, 'Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss', Thrombosis and Haemostasis, vol. 95, no. 4, pp. 689-695. https://doi.org/10.1160/TH05-11-0725
Hoffmann J, Alt A, Lin J, Lochnit G, Schubert U, Schleicher E et al. Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss. Thrombosis and Haemostasis. 2006 Apr;95(4):689-695. https://doi.org/10.1160/TH05-11-0725
Hoffmann, Jennifer ; Alt, Alex ; Lin, Jihong ; Lochnit, Günther ; Schubert, Uwe ; Schleicher, Erwin ; Chavakis, Triantaphyllos ; Brownlee, Michael ; Van der Woude, Fokko J. ; Preissner, Klaus T. ; Hammes, Hans Peter. / Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss. In: Thrombosis and Haemostasis. 2006 ; Vol. 95, No. 4. pp. 689-695.
@article{70553720e25c44c4a188f4f26f4ad569,
title = "Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss",
abstract = "Hyperglycemia-induced mitochondrial overproduction of reactive oxygen species leads to the activation of different biochemical pathways involved in endothelial damage of the diabetic retina. Tenilsetam [(±)-3-(2-thienyl)-2-piperazinone] is a dicarbonyl scavenger in the millimolar range and a transition metal ion chelator in the micromolar range. We tested its effect on experimental diabetic retinopathy, and on endothelial cell characteristics in vitro. Streptozotocin diabetic male Wistar rats (60mg/kg BW) received 50 mg/kg BW tenilsetam (D-T) for 36 weeks, or no treatment (D). The impact of tenilsetam (0-30 mM) on endothelial proliferation, apoptosis, sprouting, cytokine-induced leucocyte-endothelial interaction, and VEGF expression was tested in vitro. Tenilsetam did not affect glycemic control or body weight in diabetic animals. The 3.7 fold increase in acellular capillaries in diabetic rats [p<0.001 vs. non-diabetic controls (N)] was reduced by 70{\%} (p<0.001) through treatment, but pericyte loss (D vs. N -33{\%}; p<0.001) remained unaffected. In vitro, tenilsetam inhibited endothelial proliferation at lower doses, while inducing apoptosis at high doses. Leucocyte adhesion was only inhibited at high doses. Sprouting angiogenesis of bovine retinal endothelial cells was promoted at lower doses (≤ 10 mM). At micromolar concentrations, endothelial VEGF expression was upregulated by 100{\%}. Long-term treatment with the AGE-inhibitor and iron-chelating compound tenilsetam inhibits the formation of acellular capillaries without correcting pericyte loss. The compound has dose-dependent effects on endothelial cell function. These data suggest that, independent of known properties, tenilsetam shows important rescue functions on endothelial cells which could be useful for the treatment of early diabetic retinopathy.",
keywords = "Endothelial survival, Experimental diabetic retinopathy, Pericytes, Tenilsetam, VEGF",
author = "Jennifer Hoffmann and Alex Alt and Jihong Lin and G{\"u}nther Lochnit and Uwe Schubert and Erwin Schleicher and Triantaphyllos Chavakis and Michael Brownlee and {Van der Woude}, {Fokko J.} and Preissner, {Klaus T.} and Hammes, {Hans Peter}",
year = "2006",
month = "4",
doi = "10.1160/TH05-11-0725",
language = "English (US)",
volume = "95",
pages = "689--695",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss

AU - Hoffmann, Jennifer

AU - Alt, Alex

AU - Lin, Jihong

AU - Lochnit, Günther

AU - Schubert, Uwe

AU - Schleicher, Erwin

AU - Chavakis, Triantaphyllos

AU - Brownlee, Michael

AU - Van der Woude, Fokko J.

AU - Preissner, Klaus T.

AU - Hammes, Hans Peter

PY - 2006/4

Y1 - 2006/4

N2 - Hyperglycemia-induced mitochondrial overproduction of reactive oxygen species leads to the activation of different biochemical pathways involved in endothelial damage of the diabetic retina. Tenilsetam [(±)-3-(2-thienyl)-2-piperazinone] is a dicarbonyl scavenger in the millimolar range and a transition metal ion chelator in the micromolar range. We tested its effect on experimental diabetic retinopathy, and on endothelial cell characteristics in vitro. Streptozotocin diabetic male Wistar rats (60mg/kg BW) received 50 mg/kg BW tenilsetam (D-T) for 36 weeks, or no treatment (D). The impact of tenilsetam (0-30 mM) on endothelial proliferation, apoptosis, sprouting, cytokine-induced leucocyte-endothelial interaction, and VEGF expression was tested in vitro. Tenilsetam did not affect glycemic control or body weight in diabetic animals. The 3.7 fold increase in acellular capillaries in diabetic rats [p<0.001 vs. non-diabetic controls (N)] was reduced by 70% (p<0.001) through treatment, but pericyte loss (D vs. N -33%; p<0.001) remained unaffected. In vitro, tenilsetam inhibited endothelial proliferation at lower doses, while inducing apoptosis at high doses. Leucocyte adhesion was only inhibited at high doses. Sprouting angiogenesis of bovine retinal endothelial cells was promoted at lower doses (≤ 10 mM). At micromolar concentrations, endothelial VEGF expression was upregulated by 100%. Long-term treatment with the AGE-inhibitor and iron-chelating compound tenilsetam inhibits the formation of acellular capillaries without correcting pericyte loss. The compound has dose-dependent effects on endothelial cell function. These data suggest that, independent of known properties, tenilsetam shows important rescue functions on endothelial cells which could be useful for the treatment of early diabetic retinopathy.

AB - Hyperglycemia-induced mitochondrial overproduction of reactive oxygen species leads to the activation of different biochemical pathways involved in endothelial damage of the diabetic retina. Tenilsetam [(±)-3-(2-thienyl)-2-piperazinone] is a dicarbonyl scavenger in the millimolar range and a transition metal ion chelator in the micromolar range. We tested its effect on experimental diabetic retinopathy, and on endothelial cell characteristics in vitro. Streptozotocin diabetic male Wistar rats (60mg/kg BW) received 50 mg/kg BW tenilsetam (D-T) for 36 weeks, or no treatment (D). The impact of tenilsetam (0-30 mM) on endothelial proliferation, apoptosis, sprouting, cytokine-induced leucocyte-endothelial interaction, and VEGF expression was tested in vitro. Tenilsetam did not affect glycemic control or body weight in diabetic animals. The 3.7 fold increase in acellular capillaries in diabetic rats [p<0.001 vs. non-diabetic controls (N)] was reduced by 70% (p<0.001) through treatment, but pericyte loss (D vs. N -33%; p<0.001) remained unaffected. In vitro, tenilsetam inhibited endothelial proliferation at lower doses, while inducing apoptosis at high doses. Leucocyte adhesion was only inhibited at high doses. Sprouting angiogenesis of bovine retinal endothelial cells was promoted at lower doses (≤ 10 mM). At micromolar concentrations, endothelial VEGF expression was upregulated by 100%. Long-term treatment with the AGE-inhibitor and iron-chelating compound tenilsetam inhibits the formation of acellular capillaries without correcting pericyte loss. The compound has dose-dependent effects on endothelial cell function. These data suggest that, independent of known properties, tenilsetam shows important rescue functions on endothelial cells which could be useful for the treatment of early diabetic retinopathy.

KW - Endothelial survival

KW - Experimental diabetic retinopathy

KW - Pericytes

KW - Tenilsetam

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33645733382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645733382&partnerID=8YFLogxK

U2 - 10.1160/TH05-11-0725

DO - 10.1160/TH05-11-0725

M3 - Article

C2 - 16601840

AN - SCOPUS:33645733382

VL - 95

SP - 689

EP - 695

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -